The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs July 15)

  • Atossa Therapeutics Inc ATOS (announced results from lab studies of AT-301, its COVID-19 nasal spray drug candidate)
  • AstraZeneca plc AZN (moved on reports that it could issue an update on its coronavirus vaccine program soon)
  • Beigene Ltd BGNE
  • Bio-Rad Laboratories, Inc. Class A Common Stock BIO
  • Bio-Rad Laboratories, Inc. Class B Common Stock BIO
  • Castle Biosciences Inc CSTL (announced publication of a study demonstrating its DecisionDx-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma)
  • Catalent Inc CTLT
  • Cytokinetics, Inc. CYTK (issued an investor update on its cardiovascular pipeline)
  • ESSA Pharma Inc EPIX (announced enrollment of first patient in Phase 1 study of its prostate cancer drug)
  • Genetic Technologies Limited GENE (issued an update on its COVID-19 Severity Risk Test)
  • Heat Biologics Inc HTBX
  • Hologic, Inc. HOLX
  • Inspire Medical Systems Inc INSP
  • Moderna Inc MRNA
  • Novavax, Inc. NVAX
  • OncoSec Medical Inc ONCS
  • Qiagen NV QGEN
  • ResMed Inc. RMD
  • Principia Biopharma Inc PRNB
  • Sanofi SA SNY
  • Trevena Inc TRVN
  • Twist Bioscience Corp TWST
  • VBI Vaccines Inc VBIV
  • West Pharmaceutical Services Inc. WST

Down In The Dumps

(Biotech Stocks Hitting 52-week Lows July 15)

  • Endologix, Inc. ELGX
  • immatics biotechnologies GmbH IMTX
  • Repare Therapeutics Inc RPTX

Stocks In Focus

FDA Communicates Deficiencies In Tricida's NDA For Metabolic Acidosis Drug

Tricida Inc TCDA said it has received a notification from the FDA stating that, as part of its ongoing review of its New Drug Application for veverimer in metabolic acidosis, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. The PDUFA date is scheduled for Aug. 22.

"We continue to believe in the potential of veverimer to be disease modifying and our goal is to work with FDA to identify and resolve the issues in order to bring veverimer to patients," the company said in the release.

The stock was down 32.6% at $17.66 premarket Thursday.

Mallinckrodt's Hepatorenal Disease Drug Backed By FDA Panel In Tight Vote

Mallinckrodt PLC MNK said FDA's Cardiovascular and Renal Drugs Advisory Committee voted to recommend approval for its investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 by an 8-7 vote. HRS-1 is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.

Mallinckrodt shares were up 2.58% at $3.18 premarket Thursday.

Nabriva to Distribute Merck's Antibiotics In US

Nabriva Therapeutics PLC – ADR NBRV said it has as entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., MRK to distribute Sivextro in the U.S. and certain of its territories through Dec. 31, 2023, with renewable three-year extensions. Sivextro is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible gram-positive microorganisms.

The stock jumped 63.91% to $1.09 premarket. 

See also: The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Relay Therapeutics IPO

CytoDyn Applies For Uplisting To Nasdaq

CytoDyn Inc CYDY said it has filed a comprehensive listing application package with the Nasdaq to request an uplisting of its common stock. The company said it believes it satisfies the initial listing requirements for the exchange.

The stock edged down 0.58% to $5.10 in after-hours trading.

I-Mab To Buy Back Up To $20M In Shares

I-Mab ADR IMAB said its board has authorized a stock repurchase program to buy up to $20 million in ordinary shares in the form of ADSs.

Novartis To Make Not-for-Profit Medicine Portfolio Available At Zero Cost

Novartis AG NVS announced a new initiative to help patients in low-income and lower-middle-income countries access affordable medicines to treat the major symptoms of COVID-19.

The company said it will make the drugs available to governments, NGOs and other institutional customers in up to 79 eligible countries at zero profit.

The COVID-19 portfolio includes 15 medicines from its Sandoz division for gastrointestinal illness, acute respiratory symptoms, pneumonia and septic shock.


INmune Bio Inc INMB, which announced a positive Alzheimer's drug readout earlier this week, said it has commenced an underwritten public offering of shares of its common stock.

The stock was down 18.01% at $10.70 premarket. 

Aptose Biosciences Inc APTO said it has commenced an underwritten public offering of its common shares. All the shares to be sold in the proposed offering will be sold by the company. The company said it intends to use the net proceeds to accelerate clinical trials of CG-806 and APTO-253, acquire additional clinical assets and for working capital and general corporate purposes.

The stock was down 10.38% at $5.61 premarket. 

Cytokinetics announced plans to offer, subject to market and other conditions, $150 million in common stock in an underwritten public offering. All of the shares of common stock in the offering will be sold by the company.

The stock slid 3.31% to $28 premarket. 

Atreca Inc BCEL said it has priced its previously announced underwritten public offering of 7.03125 million shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock, each at a price of $16 per share. The company expects the offering to raise gross proceeds of $125 million, with the offering slated to close on or about July 20.

In premarket trading, the stock was down 14.77% at $15.70.

On The Radar


  • Abbott Laboratories ABT (before the market open)
  • AngioDynamics, Inc. ANGO (before the market open)
  • Johnson & Johnson JNJ (before the market open)


Cambridge, Massachusetts-based Relay Therapeutics priced its upsized offering of 20 million shares at $20, above the estimated price range of $16-$18, for raising gross proceeds of $400 million.

Relay is a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The shares will begin trading on the Nasdaq under the ticker symbol "RLAY."

Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksOfferingsFDAIPOsTrading Ideas